This 2026 review explores how cannabinoids might influence autophagy pathways relevant to Alzheimer’s disease. Its value is mainly mechanistic and hypothesis-building, with some discussion of early clinical and preclinical signals. It does not prove that cannabinoids currently offer established disease-modifying treatment for Alzheimer’s disease.
Study: Cannabis Harm Reduction Strategies
This 2025 review maps cannabis harm reduction strategies across legal, social, and health-related domains, from packaging rules and driving policies to cannabis social clubs and product testing. It is useful as a typology and policy overview, but it does not establish which measures work best because the evidence base is mixed and often qualitative. For readers and clinicians, the value here is in clearer thinking about risk reduction, not in assuming these interventions are already proven.
Cannabis Use Disorder Treatment Europe Review
CED Clinical Relevance #50 Monitored Relevance Early-stage or contextual signal requiring further evidence before action. 📋 Clinical Insight | CED Clinic Evidence Watch Cannabis Use Disorder Europe Mental Health Audience Patients, caregivers, clinicians, and...
This narrative review examines whether the endocannabinoid system may play a biochemical role in ADHD pathophysiology. It gathers 11 preclinical and 2 clinical studies and argues that ECS signaling may intersect with attention, impulsivity, and hyperactivity pathways. The core limitation is that the evidence remains thin, heavily preclinical, and far from proving that cannabinoid-based treatments are ready for clinical use in ADHD.